TAVO101

Phase 2Small molecule

TTavotek Biotherapeutics

TAVO101 is one of 42 small molecule programs targeting Atopic Dermatitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Atopic DermatitisActive, not recruiting

Atopic DermatitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

127 competitors in Atopic Dermatitis

#DrugCompanyPhaseTrials

Cytosar

Teva

Phase 3

1 2

Fludara

Sanofi

Phase 3

1 3

Adtralza

LEO Pharma

Phase 3

16 4

Amlitelimab

Sanofi

Phase 3

2 5

Certolizumab

Johnson & Johnson

Phase 3

1 6

DUPIXENT

Regeneron

Phase 3

1 7

Jaktinib

SSuzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 3

4 8

ICP-332

BBeijing InnoCare Pharma Tech Co., Ltd.

Phase 3

2 9

VC005

JJiangsu vcare pharmaceutical technology co., LTD

Phase 3

5 10

Lutikizumab

AbbVie

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Atopic Dermatitis1 trial

A Study of TAVO101 in Atopic Dermatitis Patients

Active, not recruiting·TTavotek Biotherapeutics·Phase 2·NCT06176040·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for TAVO101. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TAVO101 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TAVO101. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tavotek Biotherapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TTavotek Biotherapeutics

TAVO101

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Atopic Dermatitis1 trial

References

Drug Info

Quick Facts

Related News